Innovation in immuno-oncology: Leading companies in oncolytic viral proteins
Pharmaceutical Technology
MAY 15, 2023
A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK).
Let's personalize your content